Stockreport

Trevi Therapeutics: Late-Stage Transition Meets Execution Risk [Seeking Alpha]

Trevi Therapeutics, Inc.  (TRVI) 
PDF TRVI's strong cash position, bolstered by a $150M stock offering, funds operations into 2028 and reduces near-term financing risk. Haduvio's Phase 3 trials in IPF chr [Read more]